Purpose: Focal therapy has emerged as a novel approach to minimise adverse events without compromising oncological outcomes. This study reports oncological outcomes following focal low-dose-rate (LDR) brachytherapy for low-intermediate risk prostate cancer. Methodology: Patients were recruited from an ongoing clinical registry of focal LDR brachytherapy for low-intermediate risk prostate cancer (LIBERATE). Rigorous follow-up was conducted with surveillance mpMRI and TPBx completed at 18-36 months post-treatment. Control was achieved on repeat biopsy if there was no cancer or ISUP GG1 in <10mm of core or GG2-3 grade cancer with treatment effect. Progression occurred if there were no pathological changes from baseline or tumour upgrading. Results: Of 120 men enrolled, 54 (45.0%) have completed their repeat imaging and biopsy with a median follow-up of 38 months. Oncological control was reported in 42 (77.8%) patients, including 25 negative biopsies, 12 clinically insignificant disease, and 5 in-field lesions with treatment effect. Ten men (18.5%) had out-of-field pathological progression, of whom 7 were managed with ongoing active surveillance (5-10% pattern 4), 1 underwent salvage RARP, 1 had contralateral lobe LDR brachytherapy, and 1 proceeded to EBRT. Two men (3.7%) had concurrent out-of-field pathological progression and in-field lesions with treatment effect; of these, 1 had salvage RARP, and 1 was managed with watchful waiting. Conclusion: These early results suggest that focal LDR brachytherapy for low-intermediate risk, single lesion, imaging-visible prostate cancer demonstrates satisfactory oncological control at 18-36 months. However, further follow-up is needed to assess long-term oncological outcomes.